In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

The biomarker mid-regional pro-adrenomedullin drawn upon admission for ST-elevation myocardial infarction is a strong predictor of 30-day mortality

Session Young Investigator Awards Abstracts

Speaker Sebastian Wiberg

Congress : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : ST-Elevation Myocardial Infarction (STEMI)
  • Session type : Young Investigator Award Abstracts
  • FP Number : 381

Authors : S Wiberg (Copenhagen,DK), C Hassager (Copenhagen,DK), JE Moeller (Odense,DK), HB Ravn (Copenhagen,DK), L Holmvang (Copenhagen,DK), LO Jensen (Odense,DK), MG Lindholm (Copenhagen,DK), J Kjaergaard (Copenhagen,DK), JP Goetze (Copenhagen,DK), R Frikke-Schmidt (Copenhagen,DK), JH Thomsen (Copenhagen,DK), OK Moeller-Helgestad (Odense,DK), M Frydland (Copenhagen,DK)

Authors:
S Wiberg1 , C Hassager1 , JE Moeller2 , HB Ravn3 , L Holmvang1 , LO Jensen2 , MG Lindholm1 , J Kjaergaard1 , JP Goetze4 , R Frikke-Schmidt4 , JH Thomsen1 , OK Moeller-Helgestad2 , M Frydland1 , 1Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology - Copenhagen - Denmark , 2Odense University Hospital, Department of Cardiology - Odense - Denmark , 3Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Anaesthesia - Copenhagen - Denmark , 4Rigshospitalet - Copenhagen University Hospital, Centre of Diagnostic Investigations, Department of Clinical Chemistry - Copenhagen - Denmark ,

Citation:

Background
Despite significant improvements in ST-segment elevation myocardial infarction (STEMI) treatment during the past decades, the mortality remains high in the subset of patients developing cardiogenic shock during admission. Biomarkers that rapidly could predict the risk of death in clinically stable patients admitted with STEMI would be of high clinical value. The biomarker mid-regional pro-adrenomedullin (MRproADM) has previously been associated with increased risk of cardiogenic shock in STEMI patients. 

Purpose
To assess the associations and predictive value of MRproADM drawn upon admission versus 30-day mortality compared with the 'Thrombolysis In Myocardial Infarction' (TIMI) risk score in a large cohort of patients admitted with STEMI.

Methods
A total of 1700 consecutive patients with verified STEMI were included. We excluded patients with manifest cardiogenic shock upon admission as well as patients with out-of-hospital cardiac arrest, since these patients are known to have a high mortality. A blood sample was drawn upon admission and analyzed for MRproADM. Mortality was adjudicated after 30 days blinded for biomarker values. Cox proportional hazard models were applied to evaluate the hazard ratio (HR) MRproADM (transformed by logarithm of 2) adjusted for TIMI risk score. Further, receiver operating characteristics (ROC) curves were applied to assess the predictive value of MRproADM, the TIMI risk score and the combination of MRproADM and the TIMI risk score (Figure). 

Results
A total of 95% of patients had a valid blood sample and were included in the analyses. The mean age was 63±13 years and 1251 (74%) were male. The overall 30-day mortality was 2.8 %. The median (25th– 75thpercentile) MRproADM value was 0.70 (0.58-0.89) nmol/L in patients surviving past 30 days compared to 1.32 (1.01-2.24) nmol/L in patients dying within the first 30 days from admission (p<0.0001). MRproADM was independently associated with time to death after adjustment for TIMI risk score (HR (95% CI) 3.1 (2.3-4.3), p<0.0001). The area under the ROC curve was 0.86 for MRproADM. In contrast, the area under the ROC curve was 0.76 for the TIMI risk score (Figure). Adding TIMI risk score to MRproADM did not increase the AUC (p=0.27). 

Conclusions
The biomarker MRproADM drawn upon admission is independently associated with 30-day mortality in clinically stable patients admitted with STEMI after adjustment for TIMI risk score. Further, MRproADM is a strong predictor of 30 day mortality and seems superior to the TIMI risk score.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are